Biography
Dr. Adrian Lee is the Pittsburgh Foundation Chair and Director of the Institute for Precision Medicine (IPM), a joint effort by UPMC and the University of Pittsburgh to move biomedical research into personalized well-being and clinical care. He is also Professor of Pharmacology Chemical Biology and Human Genetics at UPMC Hillman Cancer Center. Dr. Lee received B.Sc. and Ph.D. degrees in England, and came to San Antonio, Texas for his postdoctoral studies. He was subsequently recruited to Baylor College of Medicine and to the University of Pittsburgh in 2010. The goal of Dr. Lees research laboratory is to translate basic cell and molecular research findings into the understanding and treatment of breast cancer. Dr Lee has published over 180 peer reviewed research articles. His laboratory is supported by funding from the NIH, Department of Defense, Susan G. Komen for the Cure, Breast Cancer Research Foundation, and other sources.

Biography
Dr. Dennis J. Slamon is a distinguished oncologist and researcher known for his groundbreaking breast cancer work since the late 1990s. His pioneering research led to trastuzumab (Herceptin), a targeted therapy that revolutionized treatment of HER2-positive breast cancer, significantly improving survival rates for this aggressive subtype. Dr. Slamon has continued to transform cancer research, advancing targeted therapies and precision medicine to improve patient outcomes. His work focuses on identifying molecular targets for new therapies, tailoring treatments to the specific genetic alterations in tumors. His efforts have impacted not only breast cancer but other cancers with similar molecular profiles. Throughout his career, Dr. Slamon has received prestigious awards, including the 2019 Lasker-DeBakey Clinical Medical Research Award and the 2024 Szent-Györgyi Prize for Progress in Cancer Research. He remains a leader in oncology, dedicated to advancing innovative treatments and improving the lives of cancer patients worldwide.

Biography
Dr. Pedram Razavi is a medical oncologist and physician-scientist at Memorial Sloan Kettering Cancer Center (MSK), specializing in precision oncology for breast cancer. He serves as Director of the Breast Cancer Translational Program and Molecular Tumor Board, and Director of Liquid Biopsy and Cancer Genomics for the MSK Biomarker Development Program. His research focuses on integrative clinicogenomic approaches and circulating tumor biomarkers to characterize breast cancer at both systemic and molecular levels and to expand the clinical utility of liquid biopsy technologies.Dr. Razavi earned his MD from Tehran University of Medical Sciences and his MPH and PhD in cancer epidemiology from the University of Southern California. He completed a postdoctoral fellowship at the Channing Laboratory, an internal medicine residency at USC, and a medical oncology fellowship at MSK, where he also conducted postdoctoral research in cancer genomics in the lab of Dr. José Baselga.

Biography
Mark Stewart works at Friends of Cancer Research, a Washington, DCbased organization that brings together partners across healthcare to drive advances in science, policy, and regulation that accelerate the development of cancer therapies and diagnostics. At Friends, he leads collaborative projects that create frameworks for incorporating novel clinical trial endpoints, advancing ctDNA and liquid biopsy applications, integrating real-world evidence, and applying innovative designs to make trials more efficient and representative. His work also explores emerging technologies such as AI-based tools to enhance oncology drug development, clinical trial design, and data interpretation. Through multi-stakeholder partnerships with regulators, academia, industry, and patient groups, he helps develop consensus-driven solutions that overcome barriers in drug development. These efforts have informed national policy discussions, contributed to regulatory innovation, and translated promising innovations into meaningful progress for people with cancer.

Biography
Dr. David Miyamoto is a physician scientist in the Krantz Family Center for Cancer Research at the Mass General Brigham Cancer Institute and Harvard Medical School. His translational research efforts focus on the development of novel biomarkers to guide bladder and prostate cancer therapy and improve the individualized care of each patient, with an emphasis on liquid biopsies. He has authored over 60 publications in peer-reviewed scientific journals including Science, Cell, Cancer Discovery, Nature Communications, and Lancet Oncology. His research has been supported by grants from the NIH, U.S. Department of Defense, Prostate Cancer Foundation, and Radiation Oncology Institute. Dr. Miyamoto is also a board-certified radiation oncologist specializing in treating patients with genitourinary malignancies. After receiving his AB (Chemistry), MD, and PhD (Cell and Developmental Biology) degrees from Harvard University, he completed his internship in Internal Medicine at the Brigham Women's Hospital and his residency in the Harvard Radiation Oncology Program.

Biography
Dr. DeMicheles research focuses on preventing breast cancer recurrence and metastasis with targeted drug combinations to eliminate disseminated tumor cells. Since 2005, she has been the Co-Leader of the Breast Cancer Research Program in the Abramson Cancer Center, where she also directs both the Breast Cancer Clinical Research Unit and the Breast Cancer TRACR Biobank. Dr. DeMichele has authored over 130 publications in high-impact journals such as NEJM and JAMA and has been funded by the NIH, NCI, DOD and Stand Up to Cancer. She was recently awarded the 2023 Gianni Bonadonna Breast Cancer Award from ASCO and The Conquer Cancer Foundation.

Biography
GI oncologist but has a long standing background and interest in global health, having spent time in several African countries, Haiti and India. Most recently, at MGH, she co-founded and co-leads a program called POETIC ( Program for Enhanced Training in Cancer (POETIC)) This fellowship exchange program, conducted in collaboration with Beth Israel Deaconess Medical Center Cancer Center and Lowell Schnipper, MD, trains clinical oncology fellows from the University of Cape Town in South Africa and Ocean Road Cancer Center in Tanzania.

Biography
Dr. Halla Nimeiri serves as the Chief Development Officer of Oncology at Tempus. Prior to Tempus, she held clinical development positions at Foundation Medicine and AbbVie. Dr. Nimeiri is a dedicated oncologist. She brings expertise in clinical trial design, drug development, and precision oncology. Dr. Nimeiri is an active academic clinician at Feinberg School of Medicine, where she provided transformative patient care for over 10 years. Dr. Nimeiri earned her dual fellowship in HematologyOncology from The University of Chicago.

Biography
Dr. Liu brings a wealth of experience in developing blood-based biomarkers to predict treatment benefit and outcomes in solid tumors and in developing novel therapeutics to improve survival, with a particular focus in breast cancer. She chaired the Circulating Biomarker Working Group of the Alliance for Clinical Trials in Oncology. She also co-chaired the Correlative Science Working Group and led several multi-institutional clinical trials through the Translational Breast Cancer Research Consortium. Dr. Liu most recently served as professor of oncology and chair of research in the Department of Oncology at Mayo Clinic in Rochester, MN. In her role at Mayo, she also held a dual appointment in the Department of Laboratory Medicine and Pathology and served as co-leader of the Genomics in Action Strategic Priority for the Center of Individualized Medicine.

Biography
Hilary Gee Goeckner is director of state and local campaigns for the American Cancer Society Cancer Action Network (ACS CAN), the advocacy affiliate of the American Cancer Society. In this role she leads work with ACS CAN staff and coalition partners across the country to improve access to comprehensive biomarker testing, clinical trials, fertility preservation and other health care access issues. Prior to this role, Hilary served as the Kansas government relations director for ACS CAN. Before joining ACS CAN, Hilary served as director of health policy at Kansas Action for Children. She holds a bachelors degree in anthropology and global health from Williams College and a masters degree in social work from Boston College. She lives in San Diego with her husband and two children.

Biography
Sally Werner is the CEO of Cancer Support Community (CSC), a global nonprofit dedicated to supporting individuals impacted by cancer. With over 25 years of experience as an oncology nurse and healthcare administrator, she has led clinical and operational efforts across hospitals, cancer service lines, and community-based programs. Passionate about innovation, supportive cancer care, and mission-driven leadership, she has enjoyed the last eight years at CSC. Sally lives in the Pacific Northwest with her husband and enjoys family time and the outdoors.

Biography
Dr. Bien-Willner is the Medical Director of the MolDX program at Palmetto GBA, a Medicare Administrative Contractor (MAC). He is a leader in the Precision Medicine space and practices as a Board-certified Anatomic Pathologist and Molecular Genetic Pathologist. Throughout his career, he has been active in research, development, and advancement of molecular diagnostic services, specifically next generation sequencing. He has worked closely with clinicians to develop clear clinical diagnostic and treatment pathways directing Precision Medicine programs for community cancer centers. Dr. Bien-Willner received his MD and PhD degrees from Baylor College of Medicine, with a PhD in Human Molecular Genetics. He completed his residency, fellowship, and attained a faculty appointment at Washington University in St. Louis prior to leadership roles in laboratory and biotech companies before joining Palmetto GBA.

Biography
Maximilian Diehn received his Bachelors Degree in Biochemical Sciences from Harvard College and his M.D.Ph.D. in Biophysics from Stanford University. He is a board certified Radiation Oncologist and specializes in the treatment of lung cancers. Dr. Diehns current research program spans laboratory, translational, and clinical studies. His areas of interest include cancer genomics, stem cell biology, and lung cancer biology. His work has been recognized with a variety of awards, including the V Foundation Scholar Award, the Sidney Kimmel Scholar Award, the Doris Duke Clinical Scientist Development Award, and the NIH Directors New Innovator Award. His group has developed an ultra sensitive and specific method for detection of circulating tumor DNA called CAPP-Seq. Current work is focused on applying CAPP-Seq to a range of clinical contexts, with an emphasis on tumor heterogeneity and minimal residual disease.

Biography
Luca Quagliata is the Vice President and Global Head of Medical Affairs for Thermo Fisher's Clinical Sequencing and Oncology Division. He's also a Venture Partner at xGEN VC-Fund, and serves on the boards of ACMA and IQNPath. Previously, he held key positions at the University Hospital of Basel.

Biography
Christopher Lieu, MD, is a Professor of Medicine in the Division of Medical Oncology, and Associate Director for Clinical Research at the University of Colorado School of Medicine in Aurora. He trained in internal medicine at the University of Colorado, where he also served as a Chief Medical Resident. He completed his fellowship training in medical oncology at the University of Texas MD Anderson Cancer Center in Houston and served as the Chief Medical Oncology Fellow. He currently serves as the Associate Director for Clinical Research and Director of GI Medical Oncology at the University of Colorado Cancer Center, serves on the FDA Oncologic Drugs Advisory Committee, the National Cancer Institute Colon Cancer Task Force, the National Comprehensive Cancer Network (NCCN) Panel for Neuroendocrine Cancers, and the Vice-Chair of the NCCN Board of Directors.

Biography
As a Distinguished Engineer and Uber Tech Lead at Genentech, Hugo Lam am part of the leadership team leading the organization in harnessing advanced data engineering and AI to drive scientific innovation. Dr. Lam's work focuses on building scalable, FAIR-compliant data ecosystems and fostering cross-functional collaboration to accelerate discovery and informed decision-making across the enterprise.Previously, Dr. Lam founded and led HypaHub, where I directed bioinformatics and software development initiatives aimed at AI- and data-driven diagnostics and therapeutics. Under my leadership, HypaHub became a leading biomedical startup recognized by Angels, VCs, and Y Combinator. Over five years, I oversaw product development and RD, pushing the frontiers of computational medicine.Dr. Lam's tenure earlier at Roche laid the groundwork for an innovative approach to healthcare product development through informatics research and data science, including work published in Nature Communications. We championed teamwork and effective communication, ensuring our discoveries in genomic data analysis translated into real-world applications, improving lives and shaping the future of precision medicine.